https://wiki.docmoates.com/index.php?action=history&feed=atom&title=Fenofibrate Fenofibrate - Revision history 2026-06-17T15:49:57Z Revision history for this page on the wiki MediaWiki 1.42.4 https://wiki.docmoates.com/index.php?title=Fenofibrate&diff=3976&oldid=prev Docmoates: NCLEX nursing pharmacology monographs — batch import 2026-06-17T13:37:16Z <p>NCLEX nursing pharmacology monographs — batch import</p> <p><b>New page</b></p><div>&lt;div style=&quot;border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;&quot;&gt;<br /> &#039;&#039;Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and &#039;&#039;&#039;must be verified against current manufacturer labeling before clinical use&#039;&#039;&#039;. This is educational content, not prescribing guidance.&#039;&#039;<br /> &lt;/div&gt;<br /> <br /> &#039;&#039;&#039;Fenofibrate&#039;&#039;&#039; (brand name Tricor) &amp;mdash; Antihyperlipidemic; Fibric acid derivative (fibrate).<br /> <br /> == Identification ==<br /> * &#039;&#039;&#039;Therapeutic class:&#039;&#039;&#039; Antihyperlipidemic.<br /> * &#039;&#039;&#039;Pharmacologic class:&#039;&#039;&#039; Fibric acid derivative (fibrate).<br /> <br /> == Pharmacology ==<br /> * &#039;&#039;&#039;Mechanism of action:&#039;&#039;&#039; Activates PPAR-alpha, increasing lipoprotein lipase activity to lower triglycerides and modestly raise HDL.<br /> * &#039;&#039;&#039;Onset / peak / duration:&#039;&#039;&#039; Triglyceride effect within weeks.<br /> * &#039;&#039;&#039;Half-life / therapeutic level:&#039;&#039;&#039; Half-life about 20 hours; no routine level.<br /> <br /> == Clinical use ==<br /> * &#039;&#039;&#039;Indications:&#039;&#039;&#039; Severe hypertriglyceridemia, mixed dyslipidemia.<br /> * &#039;&#039;&#039;Usual dose, route, frequency:&#039;&#039;&#039; Dose varies by formulation, generally 48 to 160 mg PO once daily.<br /> * &#039;&#039;&#039;Maximum dose / adjustments:&#039;&#039;&#039; Reduce dose in renal impairment; avoid in severe renal or hepatic disease.<br /> <br /> == Safety ==<br /> * &#039;&#039;&#039;Contraindications:&#039;&#039;&#039; Severe renal or hepatic disease, gallbladder disease, lactation.<br /> * &#039;&#039;&#039;Black box warning:&#039;&#039;&#039; None.<br /> * &#039;&#039;&#039;Interactions:&#039;&#039;&#039; Statins (rhabdomyolysis risk), warfarin (increased bleeding), cyclosporine, bile acid sequestrants.<br /> * &#039;&#039;&#039;Pregnancy / lactation:&#039;&#039;&#039; Use only if clearly needed; not recommended while breastfeeding.<br /> * &#039;&#039;&#039;High-alert:&#039;&#039;&#039; No.<br /> <br /> == Adverse effects ==<br /> * &#039;&#039;&#039;Common side effects:&#039;&#039;&#039; GI upset, elevated transaminases, back pain.<br /> * &#039;&#039;&#039;Serious effects to report:&#039;&#039;&#039; Rhabdomyolysis, gallstones, pancreatitis, hepatotoxicity.<br /> * &#039;&#039;&#039;Antidote / reversal:&#039;&#039;&#039; None.<br /> <br /> == Nursing process ==<br /> * &#039;&#039;&#039;Assessment before administration:&#039;&#039;&#039; Lipids, LFTs, renal function, gallbladder history.<br /> * &#039;&#039;&#039;Interventions during therapy:&#039;&#039;&#039; Monitor for muscle and GI symptoms; some forms require food.<br /> * &#039;&#039;&#039;Monitor:&#039;&#039;&#039; Triglycerides, LFTs, renal function, CK if symptomatic.<br /> * &#039;&#039;&#039;Evaluation / expected outcome:&#039;&#039;&#039; Triglyceride reduction.<br /> <br /> == Patient teaching ==<br /> * &#039;&#039;&#039;Patient teaching:&#039;&#039;&#039; Follow formulation-specific food instructions.<br /> * &#039;&#039;&#039;Notify provider if:&#039;&#039;&#039; Severe abdominal pain, muscle pain, dark urine.<br /> * &#039;&#039;&#039;Administration tips:&#039;&#039;&#039; Check whether your specific product is taken with food.<br /> <br /> [[Category:Other Lipid-Lowering Agents]]</div> Docmoates